Aicarm News
Cardiomyopathies explained by Prof. Franco Cecchi. Early diagnosis, treatments, and the AICARM "Listening Hearts" service.
AICARM presents its first Three-Year Strategic Plan 2026–2028, a document that marks a historic milestone in the Association's history. The Plan defines a clear vision to strengthen patient services, ensure long-term sustainability, and emphasize the centrality of people with cardiomyopathy.
LiberEtà Toscana presents AICARM through an interview with its representatives: an authentic testimony of listening, prevention, and civic engagement alongside patients with cardiomyopathy.
Support Aicarm with a donation and join the volunteers and all those who have placed their trust in us. You'll help us improve the quality of life for those living with cardiomyopathy.
The "Parents, Adolescents, and Cardiomyopathy" project, developed by AICARM with the University of Pisa, supports the emotional well-being of parents of young people diagnosed with cardiomyopathy. A research program and dedicated support groups address fears, daily challenges, and new ways of relating to their children.
Waiting lists for cardiology appointments and tests are a serious problem for people with cardiomyopathy. AICARM is launching a national collection of reports to document real difficulties, give patients a voice, and call on institutions to take concrete action to improve access to care.
On September 27, 2025, AICARM will bring the Course for Expert Patients in Cardiomyopathy to Ragusa: free training, testimonials, resuscitation for family members, and the presentation of the book Il Cuore Grande.
From book to film: A Big Heart, the first documentary film on cardiomyopathy promoted by AICARM, tells four stories of courage. Presented at the 2025 Giffoni Film Festival, it is available on TV and streaming.
Tuscany approves the first law in Italy to prevent sudden cardiac death in young people: screening in schools, resuscitation courses, and a dedicated regional registry.
After weeks of severe shortages of Ritmodan, a lifesaving drug for patients with hypertrophic obstructive cardiomyopathy, AICARM shares its commitment to ensuring continuity of treatment.
